Furthermore, compounds that disrupt the binding of S100A9 to the Toll-Like Receptor 4 (TLR4) were shown to inhibit acute EAE in mice [25], illustrating the relevance of this biomarker to MS. The gene discussed is S100A9; the disease is myeloid sarcoma.